Last edition
News about "Tzield"
US FDA Approves Sanofi's Tzield to Delay Type 1 Diabetes Progression in Children
Sanofi’s Tzield gains US FDA approval to delay stage-III Type 1 Diabetes in children aged one year and above, the first disease-modifying therapy for stage-II T1D.
Tzield | 24/04/2026 | By News Bureau
US FDA Advances Review of Tzield in Young Children
The FDA has accepted Sanofi’s sBLA for Tzield under priority review, seeking broader pediatric use in delaying type 1 diabetes onset.
Tzield | 06/01/2026 | By News Bureau | 129
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy